GlassScriptPhysician profile
Madison Rivenbark
NPI 1891214631
$3,742.25
in general payments reported to CMS, 2019-2025
22 companies · $1,254 in 2025
The $1,254 reported for 2025 was more than what 90% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $354 · 2022: $426 · 2023: $621 · 2024: $1,087 · 2025: $1,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,962.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $656.70 | 2021-2025 | Symplicity G3, Micra, Corevalve Evolut R |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $493.55 | 2022-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $370.98 | 2023-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $352.14 | 2022-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $280.99 | 2021-2025 | Farxiga, Wainua, Brilinta |
| Philips North America LLC | $228.46 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Cm9) Amb Mon & Diag Und, (5091) Amb Mon & Diag Und |
| Novartis Pharmaceuticals Corporation | $215.85 | 2022-2025 | |
| Lexicon Pharmaceuticals, INC. | $198.21 | 2023-2024 | Inpefa |
| Pfizer INC. | $161.23 | 2021-2025 | |
| Novo Nordisk INC | $116.10 | 2025 | Wegovy |
| Irhythm Technologies, INC. | $99.06 | 2024 | Zio Xt Patch, Zio Monitor |
| Abiomed | $95.19 | 2024-2025 | Impella |
| Scpharmaceuticals INC. | $82.51 | 2025 | |
| Chiesi USA, INC. | $75.75 | 2022-2025 | Kengreal |
| Amgen INC. | $70.16 | 2023-2024 | Repatha |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.74 | 2021-2023 | Jardiance |
| Boston Scientific Corporation | $42.60 | 2021-2023 | Latitude Communicator Power Supply |
| Bayer Healthcare Pharmaceuticals INC. | $39.71 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $35.46 | 2022-2023 | Xarelto |
| Alnylam Pharmaceuticals INC. | $27.64 | 2025 | Amvuttra |
| Esperion Therapeutics, INC. | $20.73 | 2023 | Nexletol |
| Myovant Sciences INC. | $15.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madison Rivenbark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.